Corbus Pharmaceuticals Holdings Inc
CRBP9.340USD
+0.030+0.32%
收盤 08/04, 16:00（美東）報價延遲15分鐘
114.25M總市值
虧損本益比TTM
關於 Corbus Pharmaceuticals Holdings Inc 公司
Corbus Pharmaceuticals Holdings, Inc. 是一家擁有多元化投資組合的精準腫瘤學公司。該公司的產品線由兩種針對實體瘤的實驗性藥物組成：CRB-701，這是一種抗體藥物偶聯物 (ADC)，靶向癌細胞上 Nectin-4 的表達以釋放細胞毒性有效載荷；CRB-601，這是一種抗整合素單克隆抗體，可阻斷癌細胞上表達的 TGFβ 的激活。其產品線還包括 CRB-913，這是一種高度外周限制的大麻素 1 型 (CB1) 受體反向激動劑，用於治療肥胖症。該公司已從加州大學舊金山分校的 Stephen Nishimura 博士的實驗室獲得了 CRB-601 的知識產權。該公司不擁有或經營製造設施，而是依靠第三方合同製造組織或許可合作伙伴爲其提供用於臨牀前和臨牀研究以及商業活動的藥物。
公司簡介
公司代碼CRBP
公司名稱Corbus Pharmaceuticals Holdings Inc
上市日期Oct 24, 2014
CEODr. Yuval Cohen, Ph.D.
員工數量28
證券類型Ordinary Share
年結日Oct 24
公司地址500 River Ridge Drive
城市NORWOOD
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02062
電話16179630103
網址https://www.corbuspharma.com/
公司代碼CRBP
上市日期Oct 24, 2014
CEODr. Yuval Cohen, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Sean F. Moran, CPA
Mr. Sean F. Moran, CPA
Chief Financial Officer
Chief Financial Officer
15.68K
-52.68%
Dr. Yuval Cohen, Ph.D.
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
14.63K
-77.23%
Mr. Alan F. Holmer, J.D.
Mr. Alan F. Holmer, J.D.
Independent Director
Independent Director
7.85K
+157.58%
Dr. Dominic Smethurst
Dr. Dominic Smethurst
Chief Medical Officer
Chief Medical Officer
6.11K
-92.09%
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Independent Director
4.80K
--
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
4.80K
--
Dr. Anne Altmeyer, Ph.D.
Dr. Anne Altmeyer, Ph.D.
Independent Director
Independent Director
3.41K
--
Dr. Ian Hodgson
Dr. Ian Hodgson
Chief Operating Officer
Chief Operating Officer
1.23K
--
Dr. John Kenneth Jenkins, M.D.
Dr. John Kenneth Jenkins, M.D.
Independent Director
Independent Director
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Sean F. Moran, CPA
Mr. Sean F. Moran, CPA
Chief Financial Officer
Chief Financial Officer
15.68K
-52.68%
Dr. Yuval Cohen, Ph.D.
Dr. Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
14.63K
-77.23%
Mr. Alan F. Holmer, J.D.
Mr. Alan F. Holmer, J.D.
Independent Director
Independent Director
7.85K
+157.58%
Dr. Dominic Smethurst
Dr. Dominic Smethurst
Chief Medical Officer
Chief Medical Officer
6.11K
-92.09%
Dr. Yong Ben, M.D., Ph.D.
Dr. Yong Ben, M.D., Ph.D.
Independent Director
Independent Director
4.80K
--
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Independent Chairman of the Board
Independent Chairman of the Board
4.80K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月28日 週一
更新時間: 7月28日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Cormorant Asset Management, LP
19.41%
OrbiMed Advisors, LLC
9.58%
Octagon Capital Advisors LP
9.11%
BlackRock Institutional Trust Company, N.A.
6.46%
The Vanguard Group, Inc.
4.90%
Other
50.54%
持股股東
持股股東
佔比
Cormorant Asset Management, LP
19.41%
OrbiMed Advisors, LLC
9.58%
Octagon Capital Advisors LP
9.11%
BlackRock Institutional Trust Company, N.A.
6.46%
The Vanguard Group, Inc.
4.90%
Other
50.54%
股東類型
持股股東
佔比
Hedge Fund
49.09%
Investment Advisor
16.03%
Investment Advisor/Hedge Fund
12.17%
Private Equity
9.58%
Venture Capital
3.52%
Bank and Trust
1.74%
Research Firm
1.40%
Individual Investor
0.61%
Pension Fund
0.07%
Other
5.79%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
246
11.50M
94.01%
-3.45M
2025Q1
251
11.62M
94.98%
-3.51M
2024Q4
256
12.27M
100.79%
-2.94M
2024Q3
245
12.92M
107.22%
+703.14K
2024Q2
212
12.40M
115.98%
+3.38M
2024Q1
167
10.08M
102.86%
+5.32M
2023Q4
134
960.97K
21.74%
-489.88K
2023Q3
143
765.13K
17.31%
-695.27K
2023Q2
165
756.43K
17.12%
-730.85K
2023Q1
205
764.30K
18.94%
-373.63K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Cormorant Asset Management, LP
2.38M
19.41%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
1.17M
9.58%
--
--
Mar 31, 2025
Octagon Capital Advisors LP
1.11M
9.11%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
790.90K
6.46%
-27.90K
-3.41%
Mar 31, 2025
The Vanguard Group, Inc.
672.06K
5.49%
+12.86K
+1.95%
Mar 31, 2025
Prosight Capital
575.14K
4.7%
+305.14K
+113.01%
Mar 31, 2025
RA Capital Management, LP
430.18K
3.52%
+430.18K
--
Feb 02, 2024
Paradigm BioCapital Advisors LP
399.66K
3.27%
+399.66K
--
Jan 26, 2024
Renaissance Technologies LLC
345.20K
2.82%
+206.10K
+148.17%
Mar 31, 2025
Exome Asset Management LLC
289.69K
2.37%
+289.69K
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
Pacer WealthShield ETF
0%
Harbor Health Care ETF
0%
ProShares Hedge Replication ETF
0%
Tema Oncology ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Vanguard US Momentum Factor ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.02%
Pacer WealthShield ETF
佔比0%
Harbor Health Care ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Tema Oncology ETF
佔比0%
Schwab U.S. Broad Market ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
Vanguard US Momentum Factor ETF
佔比0%
Fidelity Enhanced Small Cap ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
公告日期
類型
比率
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
Feb 13, 2023
Merger
30<1
